Here's Why Spark Therapeutics Inc. Is Soaring Today

After reporting second-quarter results that contained upbeat clinical news, Spark Therapeutics (NASDAQ: ONCE), a clinical-stage company focused on gene therapy, rose 18% as of 12:30 p.m. EDT on Wednesday.

Here's a review of the key highlights from the quarter that have traders feeling giddy today:

Katherine High, Spark's president and chief scientific officer, expressed her enthusiasm for the early clinical data related to SPK-8011: "The encouraging start of our SPK-8011 clinical trial reinforces the strength of our gene therapy platform, delivers human proof-of-concept in a second liver-mediated disease -- a significant achievement in the gene therapy field -- and positions us well to potentially transform the current treatment approach for this life-altering disease with a one-time intervention."

Source: Fool.com